Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study
Publication
, Conference
Wang, A; Heitner, SB; Jacoby, D; Lester, S; Fang, L; Balaratnam, G; Sehnert, AJ
Published in: EUROPEAN HEART JOURNAL
October 1, 2019
Duke Scholars
Published In
EUROPEAN HEART JOURNAL
EISSN
1522-9645
ISSN
0195-668X
Publication Date
October 1, 2019
Volume
40
Start / End Page
65 / 65
Location
Paris, FRANCE
Publisher
OXFORD UNIV PRESS
Conference Name
Congress of the European-Society-of-Cardiology (ESC) / World Congress of Cardiology
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Wang, A., Heitner, S. B., Jacoby, D., Lester, S., Fang, L., Balaratnam, G., & Sehnert, A. J. (2019). Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study. In EUROPEAN HEART JOURNAL (Vol. 40, pp. 65–65). Paris, FRANCE: OXFORD UNIV PRESS.
Wang, A., S. B. Heitner, D. Jacoby, S. Lester, L. Fang, G. Balaratnam, and A. J. Sehnert. “Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study.” In EUROPEAN HEART JOURNAL, 40:65–65. OXFORD UNIV PRESS, 2019.
Wang A, Heitner SB, Jacoby D, Lester S, Fang L, Balaratnam G, et al. Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study. In: EUROPEAN HEART JOURNAL. OXFORD UNIV PRESS; 2019. p. 65–65.
Wang, A., et al. “Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study.” EUROPEAN HEART JOURNAL, vol. 40, OXFORD UNIV PRESS, 2019, pp. 65–65.
Wang A, Heitner SB, Jacoby D, Lester S, Fang L, Balaratnam G, Sehnert AJ. Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study. EUROPEAN HEART JOURNAL. OXFORD UNIV PRESS; 2019. p. 65–65.
Published In
EUROPEAN HEART JOURNAL
EISSN
1522-9645
ISSN
0195-668X
Publication Date
October 1, 2019
Volume
40
Start / End Page
65 / 65
Location
Paris, FRANCE
Publisher
OXFORD UNIV PRESS
Conference Name
Congress of the European-Society-of-Cardiology (ESC) / World Congress of Cardiology
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology